Judge denies motion to block Exubera sales

Share this article:
A federal judge in New York on Thursday denied a motion filed by Novo Nordisk that would have blocked sales of Pfizer’s inhaled insulin Exubera. The preliminary injunction was requested by Novo Nordisk as part of a patent infringement case that will be heard by the same court. Novo sued Pfizer in August saying that sales of Exubera would damage future sales of Novo’s developmental inhalable insulin product AERx, projected for release in 2011. In a ruling, Judge Leonard Sand said Novo’s claims were “speculative” and that halting Exubera sales would be “contrary to the public interest.” In his 13-page ruling, Sand said a determination of the validity of the patents “will best be served through closer inspection at trial.” Jim Shehan, Novo’s general counsel for North America told Reuters the drugmaker remained confident in the strength of its patents. “We intend to keep moving forward to trial and our intention in not weakened by the way in which the judge ruled in this case,” Shehan said. No trial date has been set for the patent infringement case.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.